12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

IPX066 regulatory update

Impax submitted an NDA to FDA for IPX066 to treat idiopathic Parkinson's disease (PD). The company submitted the NDA under section 505(b)(2) of the Food,...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >